July 19, 2018
In a letter to the Senate and House subcommittees on Energy and Water Development, SNMMI President Satoshi Minoshima, MD, PhD, joined with leaders of the American Society of Nuclear Cardiology, American College of Cardiology, American College of Radiology, patient groups, radiopharmaceutical manufacturers and distributors, and medical imaging companies to urge support of a provision in both the Senate and House bills that would provide $20 million in additional funding to continue establishing domestic production of molybdenum-99 (Mo-99), from which technecium-99m (Tc-99m) is derived.
The letter points out that despite the American Medical Isotope Production Act of 2012 (AMIPA), a sufficient domestic supply has not been established. In addition, the global Mo-99 industry has been facing supply challenges, meaning patient access to important nuclear medicine procedures continues to be at risk.
The signers requested language that clearly delineates the use of the entire $20 million for NNSA’s medical isotope program and added the hope that the Department of Energy can be directed to use maximum flexibility in allowing pre-award funding for those expenses directly related to projects from the beginning of Fiscal Year 2018.